Human papillomaviruses (HPV) are causative agents of human cancers including those of the cervix and also of the head and neck; HPV16 is the most commonly found type in these diseases. The viral E2 protein regulates transcription from the viral genome by interacting with DNA-binding sequences in the HPV transcriptional control region; it also regulates replication by interacting with and recruiting the HPV replication factor E1 to the viral origin. Therefore, E2 is essential for the viral life cycle. The E2 protein interacts with several proteins involved in the cellular response to DNA damage including p53, TopBP1, and PARP. We therefore set out to establish whether DNA-damaging agents can regulate E2 activity. Here we show that UVB irradiation downregulates transcriptional activity of both HPV16 and HPV8 E2, while hydroxyurea and etoposide do not. This downregulation of E2 activity is independent of p53 function as it occurs in p53 wild type and null cell types as well as in the presence of functional HPV16 E6 that degrades p53. Using stable cell lines expressing E2 we show that this downregulation of E2 function by UVB is due to a reduction of the E2 protein half-life. The identification of the pathway(s) through which UVB downregulates E2 transcriptional activity and protein levels will present a novel target for the treatment of HPV-related diseases.
Introduction
Human papilloma viruses (HPV) infect epithelial tissue and cause a wide range of lesions; low-risk HPVs (e.g. HPV 1,6,11) cause benign neoplasias, and high-risk HPVs (e.g. HPV 16, 18, 31, 33) are implicated as a causative agent of cervical cancer. HPV16 is the most frequently detected high-risk virus in human cancers (zur Hausen, 2000) .
All HPVs encode an E2 protein that is essential for the viral life cycle. E2 controls viral transcription, is necessary for viral DNA replication, and has a role in controlling the cell cycle (Dell and Gaston, 2001 ). HPV16 E2 is a 43 kDa phosphoprotein that binds to 12 bp palindromic DNA sequences in the long control region (LCR) of the HPV genome. Following binding, E2 can either repress or activate transcription depending upon the particular PV LCR sequence, the E2 protein levels, and the cellular environment (Romanczuk et al., 1990; Bouvard et al., 1994; Steger and Corbach, 1997; Vance et al., 1999) . This regulation of transcription controls expression of the viral oncogenes E6 and E7 that interfere with p53 and pRb function thereby targeting cellular growth control mechanisms (Mantovani and Banks, 1999; Munger et al., 2001) . The HPV E2 protein also plays an essential role in the replication of the viral genome; E2 physically interacts with the viral replication factor E1 (Berg and Stenlund, 1997) facilitating efficient recruitment of E1 to the origin of replication ensuring initiation of viral DNA synthesis (Chao et al., 1999; Titolo et al., 1999) .
The E2 protein can be divided into three domains: an amino-terminal domain responsible for activation of transcription and also interaction with E1 and therefore essential for viral replication; a hinge region of indeterminate function; and a carboxy-terminal domain responsible for dimerisation and binding to DNA. In addition to interacting with the E1 protein, E2 interacts with the HPV structural protein L2 (Day et al., 1998) and has been shown to interact with a host of cellular proteins including AMF1, TBP, TFIIB, p300/CBP, and SMN (Rank and Lambert, 1995; Steger et al., 1995; Breiding et al., 1997; Strasswimmer et al., 1999; Lee et al., 2000) . E2 also interacts with several cellular proteins involved in the DNA damage response pathway: p53, TopBP1, and PARP (Massimi et al., 1999; Boner et al., 2002; Lee et al., 2002) . These interactions may alter the function of E2 and therefore modulate the viral life cycle in response to cellular stresses. Treatment with DNA-damaging agents alters the levels and functions of p53, TopBP1, and PARP in the cell (Lakin and Jackson, 1999; Herceg and Wang, 2001; Yamane et al., 2002) and therefore may regulate the function of the E2 protein through a protein-protein interaction. To test this hypothesis, we assayed the ability of a variety of DNA-damaging agents to modulate the transcriptional activity of the E2 protein.
Here, we demonstrate that UVB irradiation downregulates the ability of E2 to activate transcription. This downregulation is common to the E2 of both HPV16 (a mucosal virus) and HPV8 (a cutaneous virus), but is not common to other DNA-damaging agents tested, hydroxyurea and etoposide. This downregulation of E2 function is independent of p53 protein and is due to a reduction in E2 protein level following UVB irradiation caused by a reduction in protein half-life.
Results

UVB irradiation represses the transactivation function of HPV16 and HPV8 E2
To determine whether DNA-damaging agents could regulate the activity of E2, the effects of UVB irradiation, hydroxyurea, or etoposide treatment were assayed for their ability to alter the transactivation of the tk promoter by HPV16 E2. The cell line chosen for these studies was U2OS for the following reasons. Firstly, in this cell line, p53 is wild type and as this is one of the DNA-damaging proteins that interact with E2 this was important. p53 plays an important role in the HPV life cycle: the p53/E2 interaction is involved in the induction of apoptosis by E2 (Webster et al., 2000) , p53 represses HPV E1/E2 mediated viral DNA replication (Lepik et al., 1998) , and p53 is targeted for degradation by the E6 protein (Mantovani and Banks, 1999) . Secondly, it was noted in immunofluorescence studies that expression of HPV16 E2 in this cell line had no apparent toxic effect; in previously tested cell lines with wild-type p53, E2 causes either cell cycle arrest or apoptotic death (Webster et al., 2000) . As a consequence, we were capable of establishing stable U2OS cell lines expressing HPV16 E2 (see Figure 5 ). This latter point is of particular importance as the combination of E2 and DNA-damaging agents would be too toxic for most cell lines.
The three treatments used cause three distinct forms of DNA damage: UVB irradiation creates pyrimidine dimers and induces a G 1 arrest (Kulms and Schwarz, 2002) ; hydroxyurea is a nucleotide analog that causes an early S phase arrest (Nghiem et al., 2002) ; and etoposide causes double-stranded DNA breaks resulting in G 2 /M arrest (Tang et al., 2002) . The transactivation function of HPV16 E2 was assessed in response to DNA damage stimuli, and was measured by the E2-dependent activation of a tk promoter with six E2 upstream binding sites, ptk6E2-Luc (Vance et al., 1999) . With 10 ng of E2 present there was a 25-fold activation of the tk promoter, and UVB irradiation repressed the E2-dependant transactivation fivefold ( Figure 1a) ; compare lane 4 with lanes 5 and 6. No significant effect on the activation of the tk promoter was observed with UVB irradiation in the absence of E2. To control for cell death and general effects on transcription, all experiments for the ptk6E2-Luc in Figures 1-4 were carried out in parallel with a reporter plasmid containing only the tk promoter (ptk-Luc). Figure 1b is a summary of all these experiments showing the effect of UVB irradiation, E2, or both, on the basal level of transcription from the tk promoter. It should be noted that the levels of luciferase activity obtained with the tk promoter were 30-50-fold higher than that obtained with pGL3 alone. These control experiments show that the combination of E2 and/or UVB did not reduce the activation of the tk promoter. Figure 1a , b demonstrates that the repression of the E2 activation by UVB irradiation is dependent on E2 binding to the target promoter and it is not due to either a general effect on transcription or cell death. We next tested hydroxyurea and etoposide for their effects on E2 function. Both treatments have no significant effect on the transactivation function of E2 on the ptk6E2-Luc reporter (Figure 1c) . Again, this experiment was carried out in parallel with the ptk-Luc reporter to control for general effects on transcription and cell death, and no significant differences were observed (Figure 1d ). Finally, it should be noted that with all treatments, there was no increase in apoptosis of the U2OS cells as demonstrated by FACS analysis; Western blot of p53 levels showed a p53 induction due to DNA damage stimuli with all treatments (data not shown, see Figure 5c ). This demonstrates that the level of UVB, hydroxyurea, or etoposide treatment on the cells induced a DNA damage response without killing the cells.
HPV16 E2 is from a high-risk HPV subtype that infects mucosal epithelia; we next tested to see the effect of UVB irradiation on HPV8 E2, an HPV that infects cutaneous epithelia. With the ptk6E2-Luc reporter HPV8 E2 activates the tk promoter 20-fold, with 300 J/m 2 UVB irradiation there is a fourfold repression of this activation and at 400 J/m 2 UVB the activation by E2 is reduced to levels similar to the basal level of transcription ( Figure 2 ).
Repression of E2 transactivation function is p53 independent
Stability and turnover of p53 is altered in response to DNA-damaging agents (Lakin and Jackson, 1999) , and p53 can associate with E2, making p53 an ideal candidate for mediating repression of E2 transactivation function in response to UVB. Although hydroxyurea and etoposide induced p53 without downregulation of the E2 protein, it remained possible that UVB causes a specific modification of p53 that enables it to specifically interact with E2 and modify activity. The assessment of whether p53 is responsible for the UVB-mediated repression of E2 function was made in three ways: assaying in U2OS cells overexpressing HPV16 E6, which will degrade p53 (Mantovani and , assaying in the p53 null cell line Saos2, and finally assaying in the cervical carcinoma cell line HeLa that expresses the endogenous HPV18 E6 protein (Schwarz et al., 1985) .
The HPV16 E6 protein binds and degrades p53 and was used as a tool to identify if p53 has a role in the repression of E2 by UVB. Reporter plasmids containing the fos promoter with or without upstream p53 binding sites (Midgley et al., 2000) were assayed in the absence and presence of HPV16 E6 in U2OS cells. The fos promoter is activated 15-fold, due to endogenous p53, when there are upstream p53 binding sites ( Figure 3a) . With HPV16 E6, this activation is repressed threefold, demonstrating that E6 is repressing p53 function in U2OS cells (Figure 3a) . The presence of E6 has no significant effect on the UVB repression of E2 transactivation of ptk6E2-Luc (Figure 3b , compare lanes 5 and 6 with lanes 7 and 8) indicating that p53 is not primarily responsible for the repression of E2 by UVB. Again these experiments were carried out in parallel with the ptk-Luc reporter to control for general effects on transcription and cell death, and no significant differences were observed with E2, E6, UVB, or with combinations of all three (data not shown).
The human osteosarcoma cell line Saos2 is p53 null. In Saos2 cells, E2 activates transcription from ptk6E2-Luc by 400-fold and UVB irradiation represses this activation twofold (Figure 4a ). This result confirms that p53 is not primarily responsible for the repression of the transactivation function of E2 by UVB irradiation.
Finally, the regulation of E2 activity in response to UVB irradiation was assayed in the cervical carcinoma cell line HeLa, which expresses endogenous HPV18 E6 protein (Schwarz et al., 1985) . Again UVB irradiation significantly represses E2 transactivation of ptk6E2-Luc fourfold ( Figure 4b ). It was also of interest to test the ability of UVB to modulate the activity of E2 on an HPV transcriptional control region. This was attempted using the HPV18 LCR in HeLa cells. As shown in Figure 4d , UVB strongly represses the HPV18 LCR in the absence of E2 making the determination of the effect of UVB on the ability of E2 to regulate the HPV18 LCR impossible. This is an interesting result that is discussed later. 
UVB treatment results in the reduction of E2 protein levels
One possible explanation for the downregulation of E2 transcriptional activation following UVB irradiation is that such a treatment results in a reduction of E2 protein levels. To investigate this, we established U2OS cell lines expressing HPV16 E2. Previous studies have demonstrated that the presence of E2 and wild-type p53 results in an apoptotic or cell cycle inhibitory response (Desaintes et al., 1999; Webster et al., 2000; Wells et al., 2000) . However, during experiments investigating the colocalization of E2 with a variety of cellular proteins, it was noted that in U2OS cells there was no evidence of cell death in response to E2 expression (data not shown). Stable U2OS cell lines expressing HPV16 E2 were established by cotransfection of the E2-expressing plasmid used in the transcription assays with pcDNA3.1 that contains a neo resistance gene. The cells were then selected in G418; several E2-and non-E2-expressing clones were generated and the presence of E2 in these lines confirmed by Western blotting. Two of the E2-positive clones were then selected for further analysis. As shown in Figure 5a , UVB treatment of cells stably expressing E2 resulted in a large reduction of E2 protein levels 8 h following treatment. This was observed with both clones and this experiment has been repeated several times. This experiment was also repeated with a polyclonal antibody generated against the carboxy terminus of E2 with identical results (not shown). This demonstrated that the downregulation of E2 detected in Figure 5a was not simply due to masking of the epitope recognized by the monoclonal antibody TVG261. As a control, the induction of p53 following UVB irradiation was monitored and this is also shown in Figure 5a . To ensure that the reduction in E2 protein level is not due to a reduction in E2 mRNA amount, quantitative real-time RT-PCR was performed. There was no significant reduction in E2 mRNA in response to UVB irradiation (Figure 5b ). To confirm that not all DNA-damaging treatments result in a reduction of E2 protein levels, the E2-expressing stable clones were treated with hydroxyurea or UVB. It is clear that although both hydroxyurea and UVB increase p53 protein levels, only UVB treatments reduce E2 protein level (Figure 5c ). 
UVB treatment reduces the E2 protein half-life
The reduction of E2 protein levels described in Figure 5 could be due to either a reduction in translation of the E2 mRNA or a reduction in the E2 protein half-life. The ability of UVB irradiation to alter E2 protein half-life was therefore investigated and the results of these Figure 6 . U2OS clone B3 was chosen for these experiments as it expressed slightly more E2 than other clones (see Figure 5 ). In Figure 6a , cells were treated with the proteasome inhibitor MG132 for 30 min prior to irradiation; the MG132-containing medium was removed prior to UVB irradiation as the combination of the two treatments was toxic to the cells over an extended period (not shown). At 4 h postirradiation, where a clear reduction in E2 protein level is detected (Figure 5a ), the cells were harvested and then E2 detected using Western blotting. As is clear in this figure, the UVB irradiation has resulted in downregulation of E2 protein levels following irradiation (compare lanes 1 and 2), while in the presence of MG132 E2 protein levels have increased slightly (compare lanes 1 and 3) and the UVB treatment has not resulted in a reduction of E2 protein levels in the cells pretreated with MG132 (compare lanes 3 and 4). These results suggest that UVB irradiation results in increased turnover of the E2 protein via the proteasome. Therefore, it was determined whether UVB irradiation alters the half-life of the E2 protein, and the results of these experiments are shown in Figure 6b . Cells were labeled for 1 h with
35
S methionine 3 h post-UVB treatment and the E2 protein immunoprecipitated following harvesting of the cells at a number of time points. The immunoprecipitated samples were subjected to SDS-PAGE, the gel dried, and the radioactive bands representing E2 detected on a phosphor imager. A representative experiment is shown in Figure 6b , and two independent experiments showed that the E2 protein half-life was reduced from around 80 to 30 min following UVB treatment; a summary of the two experiments is shown in Figure 6c where the average half-life of the HPV16 E2 protein is shown in UVB treated and untreated cells. Taken together with the results in the MG132 experiment we conclude that UVB irradiation reduces E2 protein levels by reducing the half-life of the protein.
Discussion
The HPV E2 protein is dependent on interactions with viral and cellular partner proteins to activate and control viral transcription and replication, and therefore control the viral life cycle (Dell and Gaston, 2001 ). E2 interacts with several cellular proteins that respond to DNA damage; p53, PARP, and TopBP1 (Massimi et al., 1999; Boner et al., 2002; Lee et al., 2002) ; therefore, E2 function could be altered in response to DNA damage. Here we report that UVB irradiation represses the transactivation function of both HPV16 and HPV8 E2, while hydroxyurea and etoposide do not. The repression was observed in p53 wild-type and null cell lines and in epithelial and osteosarcoma cell lines, thus suggesting a common mechanism for repression of E2 function in response to UVB irradiation. The p53 protein is functionally modified in response to UVB irradiation agents (Lakin and Jackson, 1999), and Figure 6 UVB irradiation reduces the half-life of HPV16 E2. (a) MG132 pretreatment protects the E2 protein from UVB-mediated degradation. U2OS clone B3 cells were incubated for 30 min either with (lanes 3 and 4) or without (lanes 1 and 2) the proteasome inhibitor MG132 (5 mg/ml). The MG132 medium was then removed and the cells either irradiated with UVC (lanes 2 and 4) or not (lanes 1 and 3) . The cells were then harvested 4 h postirradiation and cell extracts prepared for Western blotting. Clearly, the MG132 pretreatment protects E2 from UVB-mediated degradation. This experiment has been repeated three times and the same results obtained. (b) UVB irradiation reduces the half-life of the HPV16 E2 protein. U2OS clone B3 cells were either UVB irradiated (lanes 6-10) or mock treated (lanes 1-5). At 3 h postirradiation, both sample sets of cells were labeled for 1 h with radioactive amino acids as described in Materials and methods. Following this incubation, the radioactive medium was removed and the samples chased for the indicated time periods (hours postlabeling). Cells were harvested and the labeled E2 protein immunoprecipitated. The samples were subjected to SDS-PAGE and the resulting gel dried and exposed to a phosphor imager screen. (c) The experiment shown in (b) was repeated and the bands from both experiments were quantitated using a Storm 840 Phosphorimager. This was determined in untreated and UVB treated cells and the average of the two experiments is shown along with standard error bars. Clearly, there is a significant reduction in the HPV16 E2 protein half-life following UVB treatment, from an average of 82 to 32 min p53 binds to E2; however, the repression of E2 transactivation function by UVB is independent of p53. In Figure 6 we demonstrate that the half-life of the E2 protein is reduced following UVB irradiation and it is likely that this reduction is responsible for the downregulation of E2 transcriptional activity. We also demonstrate that the HPV18 LCR is repressed by UVB in HeLa cells.
UVB irradiation elicits a well-characterized DNA damage response, and activates pathway(s) that increase HPV16 E2 protein turnover. Both HPV16 and HPV8 E2 proteins respond similarly to UVB suggesting a common response. The reduction in E2 protein levels in response to UVB and the repression of the HPV18 LCR could play a role in protecting the virus in response to UVB irradiation. Firstly, repression of the HPV18 LCR would result in a reduction of E6 and E7 levels, thereby elevating levels of p53 and pRb. These proteins are essential for mediating an appropriate cellular response to DNA-damaging agents such as UVB. Reactivation of p53 and pRb will therefore protect the cell from extensive damage and/or apoptosis thus protecting the infected cell. Secondly, the reduction in E2 level in response to UVB will reduce the level of viral replication allowing the viral genome to be repaired, and thereby maintain integrity. Thirdly, the HPV E2 protein can itself induce apoptosis (Webster et al., 2000) and therefore the presence of E2 with a DNA damage response could induce massive apoptosis in virusinfected cells. In summary, the inactivation of E6 and E7 proteins by transcriptional repression, and the reduction of the E2 protein levels, would provide an opportunity for repair of both the cellular and viral genome.
Multiple HPV LCRs are both activated and repressed in response to UVB irradiation (Ruhland and de Villiers, 2001) . Those viral LCRs that are activated by UVB may have evolved a mechanism to sustain viral transcription in the absence of E2 due to cellular stress, or even in response to stress. One such HPV, HPV77, has p53 response elements in the LCR that activate viral transcription in response to UVB (Purdie et al., 1999) .
Previous studies on the effect of E2 on the cell cycle have demonstrated that E2 causes either cell cycle arrest (Wells et al., 2000) or apoptosis (Desaintes et al., 1999; Webster et al., 2000) depending on cell type and p53 status. Here we have created HPV16 E2 stably expressing cells in the p53 wild-type cell line U2OS; this is the first report of a p53 wild-type cell line that will tolerate E2 expression. While U2OS are p53 wild-type, they are defective in expression levels of INK4a/ARF due to promoter methylation , and also express elevated levels of hMdm2 (Florenes et al., 1994) . Therefore, although the p53 protein itself is wild type, the p53 response pathway is aberrant in U2OS cells.
We also demonstrate here that UVB irradiation results in a reduction of the E2 protein half-life. Previous work on E2 and its stability has shown that the amino-terminal domain of HPV18 E2 is a target for ubiquitination, and an HPV18 E2 molecule lacking its amino-terminal domain is stabilized (Bellanger et al., 2001) . It has also been shown that HPV16 E2 is a phosphoprotein (Sanders et al., 1995) . The hinge region of BPV1 has a putative PEST degradation sequence that controls the stability of BPV1 E2, and the degradation of BPV1 E2 is directly controlled by phosphorylation of two serines within the PEST sequence (Penrose and McBride, 2000) . We propose that following UVB irradiation, the E2 protein is phosphorylated by one of the many pathways activated by UVB and that this phosphorylation targets the protein for degradation. Several cellular proteins are subject to targeted degradation following phosphorylation including E2F-1 (Vandel and Kouzarides, 1999) , cyclins (Spruck and Strohmaier, 2002) , and IkBa. Indeed IkBa is also degraded following UV irradiation (Li and Karin, 1998; Perez et al., 2000) . It is possible that HPV16 and HPV8 E2 also have similar methods to control degradation; therefore, the identification of how these proteins may be modified in response to UVB is of great interest. UVB irradiation modulates a complex range of cellular signaling pathways: direct DNA-damage-induced signaling, reactive oxygen species production, and the stimulation of a variety of known and unknown membrane-bound receptor kinase pathways (Kulms and Schwarz, 2002) . The identification of which pathway(s) are responsible for the UVB-mediated effect on E2 will aid the understanding of how E2 responds to cellular stresses. Identification of such pathways will provide targets for therapeutic intervention in HPVrelated diseases.
Materials and methods
Cell culture
U2OS, Saos2, and HeLa cells were grown in DMEM with 10% fetal calf serum (f.c.s.) (Invitrogen, Paisley, UK) and were routinely passaged every 3-4 days; all were split one in six. U2OS cell lines stably expressing HPV16 E2 (clones Bl and B3) were cotransfected with 2 mg of pCMV4-HPV16 E2 and 3 mg of pcDNA3.1 that contains a neo resistance gene, and the vector control stable U2OS cell line was cotransfected with 2 mg of pCMV4 and 3 mg of pcDNA3.1. Transfected cells were cultured in DMEM 10% f.c.s. with 0.7 mg/ml G418 (Invitrogen) and resistant colonies were selected and expanded. HPV16 E2-expressing clones were confirmed by Western blot. The stable cell lines were then grown in DMEM 10% f.c.s. with 0.7 mg/ml G418 and routinely passaged every 3-4 days, split one in six.
DNA damage protocols
UVB irradiation of cells was performed using a Bio-link BLX-312 (Flowgen, Leicestershire, UK) that emits UVB at a wavelength of 312 nm. The medium was briefly removed from all plates and the cells were irradiated with the dose of UVB as indicated in each figure legend. The medium from each plate was then returned to each plate. Hydroxyurea and etoposide (Sigma Aldrich, Dorset, UK) were added directly to the media of each plate to give the final concentration of chemical in the media as stated in each figure legend.
Transient transcription assays
U2OS, Saos2, and HeLa cells were plated out at a density of 3 Â 10 5 per 60 mm plate and 24 h later transfected using the calcium phosphate technique. The following morning the cells were washed, in the late afternoon the cells were treated with the DNA damage treatments, and 16 h later harvested. Briefly, the cells were washed two times with PBS and then lysed with 300 ml of reporter lysis buffer (Promega, Southampton, UK). After a 10-min incubation, the lysate was transferred into a 1.5 ml eppendorf tube and spun at 41C refrigerated microfuge for 10 min at maximum speed. The supernatant was transferred to a fresh tube and the pellet discarded. A volume of 80 ml of the supernatant was assayed for luciferase activity using the luciferase assay system (Promega). To standardize for cell number, a protein assay was carried out and the activities shown are expressed relative to the respective protein concentrations of the samples. No significant variation in protein concentration was observed. The assays shown are representative of three independent experiments carried out in duplicate. The ptk6E2-Luc, ptk-Luc (Vance et al., 1999) , pfos-Luc, and pfos53BS-Luc (Beniston et al., 2001) luciferase reporter plasmids have been described previously as have been the HPV16 E2 (Bouvard et al., 1994) , HPV8 E2 (Stubenrauch and Pfister, 1994) , and HPV16 E6 (Patel et al., 1999) expression vectors used in the transcription assays.
Western blotting
A total of 3 Â l0 5 U2OS-E2 stable cells were plated out in 100 mm 2 tissue culture plates and the following day the cells were UVB irradiated with 300 J/m 2 and re-fed. The cells were harvested at various time points following treatment using the following method. The cells were washed twice with PBS, then trypsinized, and washed two times with 10 ml of ice-cold PBS. The cell pellet was then resuspended in 1 ml of ice-cold PBS and transferred to a 1.5 ml eppendorf tube and pelleted. Cells were then resuspended in 100 ml of lysis buffer (0.5% NP40, 50 mm Tris pH 7.8, 150 mm NaCl with a protease inhibitor cocktail (Roche Lewes, UK) dissolved in the lysis buffer). The extracts were then incubated on ice for 30 min with occasional mixing. Following this, they were centrifuged in a refrigerated microfuge for 10 min at maximum speed at 41C. The supernatant was then removed to another tube and the cell debris discarded.
A total of 20 mg of protein extract was resuspended in SDS-PAGE sample buffer and electrophoresed through an SDS-PAGE system. The gel was blotted onto nitrocellulose membrane and probed for the presence of E2 or p53. The primary antibody used to detect E2, TVG261, was a kind gift from Merlin Hibma (Hibma et al., 1995) ; for p53 detection, the antibody DO-1 was purchased from Serotec (Oxford, UK). Following incubation with the primary antibody, an HRPconjugated a-mouse IgG was added. The membrane was then developed using ECL-PLUS (Amersham Biosciences, Buckinghamshire, UK) to detect the HRP conjugate and the membrane exposed to ECL film (Amersham Biosciences).
[
S] Metabolic labeling and immunoprecipitation
Cells were grown on 10 cm 2 dishes to 80% confluency. Cells were washed once with PBS, once with cysteine/methionine free MEM (Sigma) and then incubated with cysteine/methionine free MEM for 15 min. Cells were pulse labeled for 1 h with 200 mCi [ 35 S]-methionine/cysteine per ml (1000 mCi/mmol Amersham Biosciences) and then chased with DMEM 10% f.c.s. Cells were harvested at various time points postlabeling by trypsinization. Whole-cell extracts were prepared by resuspension of the cell pellets in lysis buffer as for Western blotting. Extracts were immunoprecipitated with an anti-E2 antibody (a kind gift from Dr Lawrence Banks). Briefly, 50 ml of cell extracts was precleared with a suspension of protein A sepharose C1-4B beads (Sigma) for 1 h at 41C. The extracts were then incubated in the presence of antibody for 1 h, fresh beads added and incubated for a further 1 h. The beads were then pelleted and washed five times with lysis buffer. The beads were then resuspended in 15 ml lysis buffer, NuPage LDS sample buffer added, heated to 701C for 10 min and then subjected to SDS-PAGE. Gels were dried and quantitation performed with a Storm 840 phosphorimager (Amersham).
MG132 treatment
Cells were pretreated with MG132 (5 mm) for 30 min prior to UVB irradiation. Following UVB treatment, the cells were placed in a medium that did not contain MG132 and then harvested at the indicated time points post-treatment for Western blotting. Western blotting was carried out as described above.
Real-time RT-PCR
Total RNA was isolated from U2OS-E2 cells using the RNeasy Minikit (Qiagen, Sussex, UK), and residual DNA was removed by DNase-I treatment according to the manufacturer's guidelines (Invitrogen). Probe and primers for the HPV16 E2 was designed using the Primer Express Software (Perkin-Elmer), those for b-actin were purchased from Applied Biosystems and conditions used as per the manufacturer. Real-time RT-PCR was performed using the Taqman EZ RT-PCR kit (Applied Biosystems), PCR conditions were as per the manufacturer's recommendations: 3 mm MnAc; 300 mm dATP, dCTP, and dGTP; 600 mm dUTP; 200 nm of each primer; 100 nm probe and 5 U rTth polymerase per reaction. PCR reactions were performed on a sequence detection system (ABI Prism 7700, Applied Biosystems) according to the manufacturer's instructions by using universal PCR conditions (601C for 30 min, 951C for 10 min, then 941C for 20 s and 621C for 1 min, in 40 cycles). Quantitation of E2 was performed using a 12-step standard curve from a pCMV4-E2 dilution series of 100-10 À5 pg. All samples were run in triplicate. Primers and probe for HPV16 E2 are: Fwd primer 5 0 CCTGAAATTATTAGGCAGCACTTG3 0 , Rev primer 5 0 GCGACGGCTTTGGTATGG3 0 ; Probe 5 0 FAM-CAAC-CACCCCGCCGCGA-TAMRA3 0 . To ensure no DNA contamination was in the RNA sample, an equivalent aliquot of DNase-I treated RNA was used in a real-time PCR reaction using Taq polymease (Applied Biosystems) and similar amplification conditions to the real-time RT-PCR reaction, no DNA was detected.
